Skip to main content

Table 1 Baseline demographics of participants in the MATE trial

From: The MATE trial: a multicentre, mixed-methodology, pilot, randomised controlled trial in neovascular age-related macular degeneration

 

Main MATE trial

Treatment arm A: SC

Treatment arm B: T&E

Mean age (years; SD)

78.98 (7.7)

78.4 (6.5)

Gender

 Female (%)

11 (55%)

11 (55%)

 Male (%)

9 (45%)

9 (45%)

BCVA (SD)

60.8 (12.5)

63.7 (10.0)

CRT (µm; SD)

414.3 (144.5)

406.6 (114.6)

  1. SC standard care, T&E treat and extend, SD standard deviation, BCVA best-corrected visual acuity, CRT central retinal thickness